# EDGAR Filing Document

**Accession Number:** 0001484565
**File Stem:** 0001193125-23-018199
**Filing Date:** 2023-1
**Character Count:** 5663
**Document Hash:** 4913a5433a97c43a42bd773c306841f5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-018199.hdr.sgml**: 20230130

**ACCESSION NUMBER**: 0001193125-23-018199

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230125

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20230130

**DATE AS OF CHANGE**: 20230130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SOLENO THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001484565
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **IRS NUMBER:** 770523891
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36593
- **FILM NUMBER:** 23565107

**BUSINESS ADDRESS:**
- **STREET 1:** 203 REDWOOD SHORES PARKWAY
- **STREET 2:** SUITE 500
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 650-213-8444

**MAIL ADDRESS:**
- **STREET 1:** 203 REDWOOD SHORES PARKWAY
- **STREET 2:** SUITE 500
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Capnia, Inc.
- **DATE OF NAME CHANGE:** 20100219

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (date of earliest event reported): January 25, 2023

------

## SOLENO THERAPEUTICS, INC.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36593** | **77-0523891** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File No.)** | **(IRS Employer**<br> **Identification Number)** |

---

#### 203 Redwood Shores Pkwy, Suite 500

#### Redwood City, CA 94065

#### (Address of principal executive offices)
(650) 213-8444

#### (Registrant's telephone number, including area code)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **symbols** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.001 par value | SLNO | NASDAQ |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**  |

---

(e) Named Executive Officer Compensation

On January 25, 2023, the Board of Directors of Soleno Therapeutics, Inc., (the "Company") following a review of the Company's executive compensation program by its Compensation Committee and recommendations, approved certain increases to the base salaries for fiscal year 2023, the payment of cash bonuses for fiscal year 2022 and certain equity awards for certain named executive officers as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Name and Principal Position** | **Fiscal Year 2023 Annual<br>Base Salary ($)<sup>(1)</sup>** | **Fiscal Year 2022 Cash<br>Bonus Award ($)** | **Options<sup>(2)</sup>** |
|  Anish Bhatnagar<br> *Chief Executive Officer* | $556800<sup>(3)</sup> | $278400 | 115000 |
|  James Mackaness<br> *Chief Financial Officer* | $400000 | $154000 | 30000 |
|  Patricia Hirano<br> *Vice President of Regulatory Affairs* | $340000 | $97800 | 20000 |
|  Kristen Yen<br> *Vice President of Clinical Operations* | $325000 | $93360 | 20000 |

---

(1) Effective as of January 1, 2023.

(2) One forty-eighth (1/48th) of the shares subject to the Option shall vest on the first month anniversary of January 1, 2023 (the Vesting Commencement Date), and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.

(3) No change from Fiscal Year 2022 Annual Base Salary.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SOLENO THERAPEUTICS, INC.** | **SOLENO THERAPEUTICS, INC.** |
| Date: January 30, 2023 |  |  |
|  | By: | /s/ Anish Bhatnagar |
|  |  | Anish Bhatnagar |
|  |  | Chief Executive Officer |

---